Appendix 1. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals.



Appendix 2. Overlayed histograms of the change in cycle length (days) between the three prevaccination cycle average and the vaccination cycle for first dose (top) or second dose (bottom). Histograms for individuals vaccinated in the follicular phase are shown in red, individuals vaccinated in the luteal phase are shown in *blue*, and overlapping distributions are shown in *purple*.



Appendix 3. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes individuals without a known ovulation date (excluded n=3,683 for first dose, n=2,155 for second dose).



Appendix 4. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes anyone with a prevaccination cycle length outside of the normal 24 to 38–day range (excluded n=2,951 for first dose, n=2,082 for second dose).



Appendix 5: Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes anyone with a prevaccination cycle flagged as anovulatory by the Natural Cycles algorithm (excluded n=874 for first dose, n=607 for second dose).



Appendix 6. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes anyone with a prevaccination follicular phase outside of the 8-to-21-day range (excluded n=4,822 for first dose, n=3,443 for second dose).



Appendix 7. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second (right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes anyone with reported polycystic ovarian syndrome or with prevaccination average cycle length over 35 days (excluded n=919 for first dose, n=661 for second dose).



Appendix 8. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Excludes anyone with reported emergency contraception use in the vaccination cycle or any prior cycle (excluded n=508 for first dose, n=481 for second dose).



Appendix 9. Unadjusted within-individual change in menstrual cycle length (in days) from three prevaccination cycle average to vaccination cycle, by timing of vaccination, for first (left) and second right) coronavirus disease 2019 (COVID-19) vaccine doses. *Error bars* represent 98.75% confidence intervals. Comparing changes in cycle length for individuals vaccinated in early and late follicular phase, early and late luteal phase, and unvaccinated. *Early* and *late subphases* are defined as the first or second half of the cycle phase, respectively.



Covariate		$1^{\text{st}}$ Dose (n = 19,497)			$2^{nd}$ dose (n = 13,942)		
		Coefficient	98.75%	p-value	Coefficient	98.75%	p-value
			Confidence			Confidence	
			Interval			Interval	
Timing of	Follicular	0.92	0.74, 1.10	< 0.001	0.94	0.72, 1.16	< 0.001
vaccination	Luteal	-0.17	-0.37, 0.03	0.089	-0.11	-0.35, 0.13	0.379
	Unvaccinated	Referent	-	-	Referent	-	-
Age group	18-24	Referent	-	-	Referent	-	-
(years)	25-29	-0.04	-0.27, 0.19	0.725	-0.08	-0.39, 0.22	0.602
	30-34	-0.12	-0.36, 0.12	0.313	-0.28	-0.59, 0.04	0.084
	35-39	-0.12	-0.40, 0.16	0.409	-0.29	-0.66, 0.08	0.126
	40-45	-0.05	-0.43, 0.34	0.811	-0.01	-0.51, 0.49	0.957
Race and	Asian	-0.07	-0.48, 0.27	0.585	-0.11	-1.01, 0.79	0.814
ethnicity	Black/African/African American	-0.10	-0.48, 0.27	0.585	0.11	-0.33, 0.56	0.619
-	Hispanic/Latina	0.16	-0.33, 0.64	0.518	0.28	-0.29, 0.85	0.329
	Middle-Eastern/North African	0.19	-0.88, 1.26	0.721	0.04	-1.26, 1.33	0.957
	Native Hawaiian/Pacific Islander	0.29	-1.16, 1.74	0.693	-0.43	-2.13, 1.28	0.625
	White	Referent	-	-	Referent	-	-
BMI	Underweight	0.36	-0.03, 0.75	0.072	0.16	-0.39, 0.71	0.563
category	Normal weight	Referent	-	-	Referent	-	-
	Overweight	0.16	-0.05, 0.37	0.131	-0.05	-0.33, 0.23	0.705
	Obese	0.22	-0.08, 0.52	0.157	0.45	0.02, 0.88	0.040
Parous		-0.08	-0.31, 0.14	0.460	-0.06	-0.35, 0.23	0.679
College deg	College degree or more		-0.27, 0.11	0.414	0.00	-0.24, 0.25	0.975
In a relation	In a relationship		-0.17, 0.26	0.673	-0.07	-0.34, 0.19	0.584
Global	UK/Channel Islands	Referent	-	-	Referent	-	-
region	Europe	-0.10	-0.27, 0.07	0.248	-0.27	-0.51, -0.04	0.021
-	USA/Canada	-0.04	-0.22, 0.14	0.663	-0.04	-0.28, 0.20	0.749
	Australia/New Zealand	-0.17	-0.54, 0.21	0.384	-0.09	-0.56, 0.38	0.700

## Appendix 10. Multivariable Modeling Estimates Following Multiple Imputation

Edelman A, Boniface ER, Male V, Cameron S, Benhar E, Han L, et al Timing of coronavirus disease 2019 (COVID-19) vaccination and effects on menstrual cycle changes. Obstet Gynecol 2024;143.

The authors provided this information as a supplement to their article.

©2024 The Authors.

Other	-0.14	-0.63, 0.34	0.561	-0.39	-1.11, 0.32	0.281
Constant	0.18	-0.15, 0.52	0.282	0.47	0.04, 0.90	0.032

Model outcomes are the within-individual change in menstrual cycle length (in days) from 3 pre-vaccination cycle average to vaccination cycle, for 1<sup>st</sup> and 2<sup>nd</sup> COVID-19 vaccine doses.

Appendix 11. Collated Sensitivity Analysis Results of the Within-Individual Change in Menstrual Cycle Length (in Days; With 98.75% Confidence intervals) From Three Prevaccination Cycle Average to Vaccination Cycle, by Timing of Vaccination (Appendices 1-8), for First and Second Coronavirus Disease 2019 (COVID-19) Vaccine Doses

Analysis Details	Appendix	1 <sup>st</sup> Dose			2 <sup>nd</sup> Dose			
	#	Follicular	Luteal	Unvaccinated	Follicular	Luteal	Unvaccinated	
Unadjusted	1	1.00	-0.10	0.09	1.10	0.05	0.21	
		(0.87, 1.13)	(-0.26, 0.07)	(-0.09 <i>,</i> 0.27)	(0.92, 1.27)	(-0.17 <i>,</i> 0.27)	(0.00, 0.41)	
Excluding anyone without	3	0.75	-0.03	0.09	0.87	0.09	0.21	
known ovulation date		(0.62, 0.89)	(-0.22 <i>,</i> 0.15)	(-0.07 <i>,</i> 0.26)	(0.68, 1.06)	(-0.15 <i>,</i> 0.34)	(0.01, 0.40)	
Excluding anyone with pre-	4	0.88	0.02	0.09	1.00	0.07	0.28	
vaccination cycles outside		(0.77, 0.99)	(-0.12 <i>,</i> 0.16)	(-0.07 <i>,</i> 0.25)	(0.85, 1.16)	(-0.13, 0.26)	(0.09 <i>,</i> 0.46)	
24-38 day range								
Excluding anyone with an	5	0.92	-0.10	0.04	0.97	0.02	0.12	
anovulatory pre-vaccination		(0.80, 1.05)	(-0.26 <i>,</i> 0.06)	(-0.13, 0.21)	(0.80, 1.14)	(-0.20, 0.22)	(-0.07, 0.32)	
cycle								
Excluding anyone with pre-	6	0.96	0.19	0.34	1.06	0.19	0.39	
vaccination follicular phase		(0.85, 1.07)	(0.06, 0.33)	(0.19, 0.50)	(0.91, 1.21)	(0.01, 0.38)	(0.22, 0.56)	
outside 8-21 day range								
Excluding anyone with	7	0.98	-0.02	0.19	1.10	0.12	0.28	
PCOS* or pre-vaccination		(0.86, 1.10)	(-0.17 <i>,</i> 0.13)	(0.02, 0.36)	(0.93, 1.26)	(-0.09 <i>,</i> 0.32)	(0.09, 0.47)	
cycle length > 35 days								
Excluding anyone with	8	0.99	-0.10	0.06	1.07	0.05	0.18	
reported emergency		(0.87, 1.12)	(-0.26 <i>,</i> 0.07)	(-0.12, 0.24)	(0.89, 1.25)	(-0.18, 0.27)	(-0.02, 0.39)	
contraception in study								
cycles								

\* PCOS = polycystic ovarian syndrome

Edelman A, Boniface ER, Male V, Cameron S, Benhar E, Han L, et al Timing of coronavirus disease 2019 (COVID-19) vaccination and effects on menstrual cycle changes. Obstet Gynecol 2024;143.

The authors provided this information as a supplement to their article.

©2024 The Authors.

Appendix 12. Sensitivity Analysis Results of the Within-Individual Change in Menstrual Cycle Length (in Days With 98.75% Confidence Intervals) From Three Prevaccination Cycle Average to Vaccination Cycle, by Timing of Vaccination for Early and Late Subphases (Appendix 9), for First and Second Coronavirus Disease 2019 (COVID-19) Vaccine Doses

1 <sup>st</sup> Dose					2 <sup>nd</sup> Dose				
Early	Late	Early Luteal	Late	Unvaccinated	Early	Late	Early	Late Luteal	Unvaccinated
Follicular	Follicular		Luteal		Follicular	Follicular	Luteal		
1.09	0.89	-0.05	-0.15	0.09	1.15	1.03	0.09	0.00	0.21
(0.92, 1.26)	(0.70, 1.08)	(-0.27, 0.17)	(-0.40, 0.10)	(-0.09, 0.27)	(0.91, 1.39)	(0.76, 1.30)	(-0.21, 0.38)	(-0.33, 0.34)	(0.00, 0.41)